New drug cocktail aims to tackle Hard-to-Treat stomach cancer
NCT ID NCT07680569
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study tests a new biologic drug called HCB101 in combination with other cancer drugs (zolbetuximab and chemotherapy) for people with advanced gastric or gastro-esophageal cancer. The goal is to find a safe dose and see if the combination can shrink tumors. About 40 adults will take part, and the study will monitor side effects and how well the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HCB101 (a biologic drug) combined with zolbetuximab and chemotherapy (oxaliplatin, 5-fluorouracil, leucovorin)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced gastric or gastro-esophageal cancer that has not responded to standard therapies.
What could go wrong
This is an early-phase trial with a small number of participants, so the benefits are uncertain. Side effects from the drug combination may be significant, and the treatment may not shrink tumors or improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Retlirafusp alfa + chemo for gastric cancer with NCT07677293
- Paclitaxel+Fruquintinib for Advanced Gastric Can NCT07552402
- CAR-NK Cell Therapy for Advanced Stomach Cancer NCT07551362
- Gastric Cancer Trial: Fruquintinib Combo After P NCT06417892
- iGreenGO Study: ICG in Gastric Cancer Surgery (NCT04943484)
- Anlotinib Combo for Advanced Gastric Cancer Tria NCT06939452
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••